Indaptus Therapeutics, Inc. - Common Stock (INDP)
CUSIP: 45339J105
Q4 2024 13F Holders as of 31 Dec 2024
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 111,087,302
- Total 13F shares
- 638,409
- Share change
- +29,489
- Total reported value
- $539,564
- Price per share
- $0.84
- Number of holders
- 19
- Value change
- +$18,707
- Number of buys
- 7
- Number of sells
- 3
Quarterly Holders Quick Answers
What is CUSIP 45339J105?
CUSIP 45339J105 identifies INDP - Indaptus Therapeutics, Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Related Filing Research
- Latest 13F filings for newly reported positions.
- Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
- Latest 10-Q/10-K reports for financial context tied to this issuer.
- Recent insider transactions for executive and insider activity.
- SEC investors directory and top value investors for manager drilldown.
- Back to full security ownership history.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 45339J105:
Top shareholders of INDP - Indaptus Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Glen R. Anderson |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,190,400
|
$2,785,536 | — | 10 Aug 2023 | |
| Hoonmo Lee |
3/4/5
|
Director |
—
mixed-class rows
|
708,272
mixed-class rows
|
$1,626,157 | — | 04 Aug 2021 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.23%
|
256,265
|
$317,769 | — | 30 Sep 2024 | |
| INVESTMENT HOUSE LLC |
13F
|
Company |
0.09%
|
99,976
|
$123,970 | — | 30 Sep 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.07%
|
73,129
|
$90,691 | — | 30 Sep 2024 | |
| STRATEGY ASSET MANAGERS LLC |
13F
|
Company |
0.04%
|
45,336
|
$56,217 | — | 30 Sep 2024 | |
| Pine Valley Investments Ltd Liability Co |
13F
|
Company |
0.04%
|
43,983
|
$54,539 | — | 30 Sep 2024 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.02%
|
27,100
|
$33,604 | — | 30 Sep 2024 | |
| Vivaldi Capital Management LP |
13F
|
Company |
0.02%
|
24,000
|
$29,760 | — | 30 Sep 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.01%
|
15,390
|
$19,084 | — | 30 Sep 2024 | |
| STATE STREET CORP |
13F
|
Company |
0.01%
|
13,073
|
$16,211 | — | 30 Sep 2024 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0%
|
4,812
|
$5,967 | — | 30 Sep 2024 | |
| Roger J. Waltzman |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
75,000
|
$5,325 | — | 09 Oct 2024 | |
| Boyan Vesselinov Litchev |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
1,150
|
$2,691 | — | 01 Feb 2022 | |
| MORGAN STANLEY |
13F
|
Company |
0%
|
884
|
$1,097 | — | 30 Sep 2024 | |
| Brian O'Callaghan |
3/4/5
|
Director |
—
class O/S missing
|
13,750
|
$976 | — | 30 Sep 2022 | |
| UBS Group AG |
13F
|
Company |
0%
|
522
|
$647 | — | 30 Sep 2024 | |
| Bangor Savings Bank |
13F
|
Company |
0%
|
400
|
$496 | — | 30 Sep 2024 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0%
|
64
|
$79 | — | 30 Sep 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
60
|
$74 | — | 30 Sep 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0%
|
19
|
$24 | — | 30 Sep 2024 | |
| GROUP ONE TRADING LLC |
13F
|
Company |
0%
|
7
|
$9 | — | 30 Sep 2024 | |
| DANSKE BANK A/S |
13F
|
Company |
0%
|
1
|
$1 | — | 30 Sep 2024 |
Institutional Holders of Indaptus Therapeutics, Inc. - Common Stock (INDP) as of Q4 2024
As of 31 Dec 2024,
Indaptus Therapeutics, Inc. - Common Stock (INDP) was held by
19 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
638,409 shares.
The largest 10 holders included
VANGUARD GROUP INC, INVESTMENT HOUSE LLC, GEODE CAPITAL MANAGEMENT, LLC, STRATEGY ASSET MANAGERS LLC, Pine Valley Investments Ltd Liability Co, RENAISSANCE TECHNOLOGIES LLC, Vivaldi Capital Management LP, SUSQUEHANNA INTERNATIONAL GROUP, LLP, TWO SIGMA SECURITIES, LLC, and STATE STREET CORP.
This page lists
20
institutional shareholders reporting positions in this security
for the Q4 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2024 vs Q3 2024 Across Filers
Q3 2024 holders
17
Q4 2024 holders
19
Holder diff
2
| Investor | Q3 2024 Shares | Q4 2024 Shares | Share Diff | Share Chg % | Q3 2024 Value $ | Q4 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.